TNK vs tirofiban for heart attack with large clot
Part of Heart & circulation clinical trials.
This trial tests a clot-busting drug (TNK) versus a blood thinner (tirofiban) in people having a major heart attack with a large clot. If you qualify, you would get the medicine directly into your heart artery through a thin tube to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are having a severe heart attack that started within the last 12 hours.
- A heart catheterization shows a large clot or slow blood flow even after a balloon or clot suction.
- You will have the procedure done through the artery in your wrist (radial artery).
- You do not have conditions like severe bleeding risk, kidney failure, or other serious illnesses listed in the full criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.
This trial compares two clot-dissolving medications (tenecteplase and reteplase) given before a procedure to remove a large clot from a brain artery. It aims to see which drug works better for people who have had an acute ischemic stroke and are eligible for both treatments.
This trial tests whether adding a clot-busting medication (rhTNK-tPA) before a clot-removal procedure (thrombectomy) can improve outcomes for people who have a moderate-to-severe stroke and arrive at the hospital 4.5 to 24 hours after symptoms start. It's for those with a large artery blockage but still enough brain tissue that can be saved.
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
This trial looks at giving a clot-busting medicine directly into the brain arteries (intra-arterial TNK) when a stroke procedure (thrombectomy) doesn’t reopen the blocked vessel enough. It aims to improve recovery by improving blood flow while checking for safety, especially bleeding risk.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
Hear when a new ST-segment Elevation Myocardial Infarction (STEMI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.